A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020
Phase 2
Completed
- Conditions
- Alzheimer Disease
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2010-01-29
- Lead Sponsor
- Eisai Limited
- Registration Number
- NCT00165659
The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia
Phase 3
Completed
- Conditions
- Dementia With Parkinson's Disease
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2013-05-10
- Lead Sponsor
- Eisai Limited
- Registration Number
- NCT00165815
- Locations
- 🇮🇪
Belfast City Hospital, Belfast, Ireland
🇮🇪Unit 20 Black Poo Technology Centerl, Blackpool, Ireland
🇩🇪Parkinson Klinik Wolfach, Wolfach, Germany
Randomized, Open, Parallel, Active Controlled Study on Fracture Prevention in Antiosteoporosis Treatment (OF Study)
Phase 4
Completed
- Conditions
- Osteoporosis
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2010-01-29
- Lead Sponsor
- Eisai Limited
- Registration Number
- NCT00165607
A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2008-12-09
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 540
- Registration Number
- NCT00165633
An Open Label Phase II Study of Indisulam in Combination With Irinotecan in Patients With Metastatic Colorectal Cancer Who Have Been Previously Treated With 5-Fluorouracil/Leucovorin and Oxaliplatin
Phase 2
Completed
- Conditions
- Colorectal Cancer
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2006-10-09
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 40
- Registration Number
- NCT00165867
- Locations
- 🇬🇧
Cookridge Hospital, Leeds, United Kingdom
🇬🇧Aberdeen Royal Infirmary, Aberdeen, United Kingdom
🇫🇷Hôpitaux Civils de Colmar, Colmar, France
The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment
Phase 2
Completed
- Conditions
- Cognitive Impairment
- First Posted Date
- 2005-02-18
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 165
- Registration Number
- NCT00103948
- Locations
- 🇺🇸
New York University School of Medicine, New York, New York, United States
🇺🇸Jose Biller, M.D., Maywood, Illinois, United States
© Copyright 2025. All Rights Reserved by MedPath